<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>The expression of the multidrug resistance (<z:chebi fb="14" ids="53218">MDR</z:chebi>) phenotype is connected with the overexpression of P-<z:chebi fb="2" ids="17089">glycoprotein</z:chebi> </plain></SENT>
<SENT sid="1" pm="."><plain>By applying the immunocytochemical assay we have demonstrated that in <z:mpath ids='MPATH_512'>myeloproliferative diseases</z:mpath> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e>, ALL, <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>, <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CGL</z:e>), in single cases, in smear preparations from the peripheral blood and bone marrow the cells with <z:chebi fb="14" ids="53218">MDR</z:chebi>-positive phenotype can be detected in the material obtained from patients before therapy, and without clinically and anamnestically known exposure to cytotoxic or immunosuppressive drugs </plain></SENT>
<SENT sid="2" pm="."><plain>This finding has demonstrated the presence of subpopulations of <z:chebi fb="14" ids="53218">MDR</z:chebi>-positive cells in <z:hpo ids='HP_0001909'>leukemias</z:hpo> and <z:hpo ids='HP_0002863'>myelodysplastic syndromes</z:hpo> already before therapy, and, furthermore, has evidenced that a positive <z:chebi fb="14" ids="53218">MDR</z:chebi> phenotype is not necessarily associated with a malignant phenotype of a malignant cell transformation </plain></SENT>
</text></document>